BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 35663979)

  • 1. Autophagy and the Bone Marrow Microenvironment: A Review of Protective Factors in the Development and Maintenance of Multiple Myeloma.
    Hamedi KR; Harmon KA; Goodwin RL; Arce S
    Front Immunol; 2022; 13():889954. PubMed ID: 35663979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Runx2 Deficiency in Osteoblasts Promotes Myeloma Resistance to Bortezomib by Increasing TSP-1-Dependent TGFβ1 Activation and Suppressing Immunity in Bone Marrow.
    Zhang C; Xu X; Trotter TN; Gowda PS; Lu Y; Suto MJ; Javed A; Murphy-Ullrich JE; Li J; Yang Y
    Mol Cancer Ther; 2022 Feb; 21(2):347-358. PubMed ID: 34907087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A plastic SQSTM1/p62-dependent autophagic reserve maintains proteostasis and determines proteasome inhibitor susceptibility in multiple myeloma cells.
    Milan E; Perini T; Resnati M; Orfanelli U; Oliva L; Raimondi A; Cascio P; Bachi A; Marcatti M; Ciceri F; Cenci S
    Autophagy; 2015; 11(7):1161-78. PubMed ID: 26043024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modeling multiple myeloma-bone marrow interactions and response to drugs in a 3D surrogate microenvironment.
    Belloni D; Heltai S; Ponzoni M; Villa A; Vergani B; Pecciarini L; Marcatti M; Girlanda S; Tonon G; Ciceri F; Caligaris-Cappio F; Ferrarini M; Ferrero E
    Haematologica; 2018 Apr; 103(4):707-716. PubMed ID: 29326121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dissecting the multiple myeloma-bone microenvironment reveals new therapeutic opportunities.
    Shay G; Hazlehurst L; Lynch CC
    J Mol Med (Berl); 2016 Jan; 94(1):21-35. PubMed ID: 26423531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stew in its Own Juice: Protein Homeostasis Machinery Inhibition Reduces Cell Viability in Multiple Myeloma Cell Lines.
    de Oliveira MB; Sanson LFG; Eugenio AIP; Barbosa-Dantas RSS; Colleoni GWB
    Curr Mol Med; 2019; 19(2):112-119. PubMed ID: 30834832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone Marrow Stromal Cells-Induced Drug Resistance in Multiple Myeloma.
    Ria R; Vacca A
    Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31963513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autophagy and Apoptosis: Current Challenges of Treatment and Drug Resistance in Multiple Myeloma.
    Al-Odat OS; Guirguis DA; Schmalbach NK; Yao G; Budak-Alpdogan T; Jonnalagadda SC; Pandey MK
    Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36614089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Old and Young Actors Playing Novel Roles in the Drama of Multiple Myeloma Bone Marrow Microenvironment Dependent Drug Resistance.
    Manni S; Carrino M; Semenzato G; Piazza F
    Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29783691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumour-associated macrophage-mediated survival of myeloma cells through STAT3 activation.
    De Beule N; De Veirman K; Maes K; De Bruyne E; Menu E; Breckpot K; De Raeve H; Van Rampelbergh R; Van Ginderachter JA; Schots R; Van Valckenborgh E; Vanderkerken K
    J Pathol; 2017 Mar; 241(4):534-546. PubMed ID: 27976373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autophagy-related mechanisms for treatment of multiple myeloma.
    Kozalak G; Koşar A
    Cancer Drug Resist; 2023; 6():838-857. PubMed ID: 38239705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. System Xc
    Wang F; Oudaert I; Tu C; Maes A; Van der Vreken A; Vlummens P; De Bruyne E; De Veirman K; Wang Y; Fan R; Massie A; Vanderkerken K; Shang P; Menu E
    Cancer Lett; 2022 Jun; 535():215649. PubMed ID: 35315341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NRF2 Is One of the Players Involved in Bone Marrow Mediated Drug Resistance in Multiple Myeloma.
    Yen CH; Hsiao HH
    Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30405034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Proteasome Inhibitor Bortezomib Maintains Osteocyte Viability in Multiple Myeloma Patients by Reducing Both Apoptosis and Autophagy: A New Function for Proteasome Inhibitors.
    Toscani D; Palumbo C; Dalla Palma B; Ferretti M; Bolzoni M; Marchica V; Sena P; Martella E; Mancini C; Ferri V; Costa F; Accardi F; Craviotto L; Aversa F; Giuliani N
    J Bone Miner Res; 2016 Apr; 31(4):815-27. PubMed ID: 26551485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Halting pro-survival autophagy by TGFβ inhibition in bone marrow fibroblasts overcomes bortezomib resistance in multiple myeloma patients.
    Frassanito MA; De Veirman K; Desantis V; Di Marzo L; Vergara D; Ruggieri S; Annese T; Nico B; Menu E; Catacchio I; Ria R; Racanelli V; Maffia M; Angelucci E; Derudas D; Fumarulo R; Dammacco F; Ribatti D; Vanderkerken K; Vacca A
    Leukemia; 2016 Mar; 30(3):640-8. PubMed ID: 26487273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myeloma cells exhibit an increase in proteasome activity and an enhanced response to proteasome inhibition in the bone marrow microenvironment in vivo.
    Edwards CM; Lwin ST; Fowler JA; Oyajobi BO; Zhuang J; Bates AL; Mundy GR
    Am J Hematol; 2009 May; 84(5):268-72. PubMed ID: 19296472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Role of Marrow Microenvironment in the Growth and Development of Malignant Plasma Cells in Multiple Myeloma.
    Giannakoulas N; Ntanasis-Stathopoulos I; Terpos E
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33923357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sphingosine kinase 2 inhibition synergises with bortezomib to target myeloma by enhancing endoplasmic reticulum stress.
    Wallington-Beddoe CT; Bennett MK; Vandyke K; Davies L; Zebol JR; Moretti PAB; Pitman MR; Hewett DR; Zannettino ACW; Pitson SM
    Oncotarget; 2017 Jul; 8(27):43602-43616. PubMed ID: 28467788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of the ʟ-glutamine transporter ASCT2 sensitizes plasma cell myeloma cells to proteasome inhibitors.
    Prelowska MK; Mehlich D; Ugurlu MT; Kedzierska H; Cwiek A; Kosnik A; Kaminska K; Marusiak AA; Nowis D
    Cancer Lett; 2021 Jun; 507():13-25. PubMed ID: 33713737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CCR10/CCL27 crosstalk contributes to failure of proteasome-inhibitors in multiple myeloma.
    Thangavadivel S; Zelle-Rieser C; Olivier A; Postert B; Untergasser G; Kern J; Brunner A; Gunsilius E; Biedermann R; Hajek R; Pour L; Willenbacher W; Greil R; Jöhrer K
    Oncotarget; 2016 Nov; 7(48):78605-78618. PubMed ID: 27732933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.